The pressure is on for those earnings to support the market's current valuations, after weeks of choppy trading.» Read More
If you can move somewhat swiftly, Cramer thinks 4 stocks present opportunity right here, right now.
Nov 13- U.S. health regulators on Wednesday approved a drug to treat a rare and aggressive form of non-Hodgkin lymphoma developed by Johnson& Johnson and Pharmacyclics Inc, becoming the second drug that had received the FDA's new breakthrough therapy designation to gain approval.
Nov 13- U.S. health regulators on Wednesday approved a drug to treat a rare and aggressive form of non-Hodgkin lymphoma developed by Johnson& Johnson and Pharmacyclics Inc, marking the second drug that received the FDA's new breakthrough therapy designation to gain approval.
Stocks are at record highs and Wall Street is getting feverishly bullish. What could possibly go wrong?
Oct 24- Celgene Corp raised its earnings forecast for 2013 on Thursday after reporting slightly higher-than-expected quarterly profit on robust sales of its flagship blood cancer drug Revlimid and solid growth in newer cancer treatments.
U.S. stock index futures signaled a higher open on Thursday, with markets still boosted by raised hopes the Federal Reserve will not start tapering off its asset purchases until next year.
Oct 24- Celgene Corp on Thursday reported a slightly higher-than-expected third-quarter profit as sales of its flagship blood cancer drug Revlimid and of Abraxane for breast and lung cancer grew, and the company raised its 2013 earnings forecast.
Oct 24- Celgene Corp on Thursday reported lower third-quarter profit on higher costs, but sales of its flagship blood cancer drug Revlimid and of Abraxane for breast and lung cancer grew and the company raised its 2013 earnings forecast. Excluding special items, Celgene earned $1.56 per share.
With stocks near record highs, strategists are recommending investors focus on stock-picking select names and sectors, rather than the broader market.
Carl Icahn knew not only when to get in but when to get out of Netflix and even had to overrule his own son in making the decision.
Biotech stocks are some of Nasdaq's best performing this year. Joel Sendek, Stifel Nicolaus, looks at names leading the biotech boom.
Sure the shutdown could become frightening. But Cramer doesn’t want it to scare you out of stocks entirely.
Cramer says these 10 stocks are still 'buys' even if the DC debt debacle gets really nasty.
Want to avoid taking a hit on your portfolio because of troubles in Washington? Cramer found one sector that will be a shelter from the storm.
There are a handful of stocks out there that the market loves and should take even higher by the end of the year, CNBC's Jim Cramer said Thursday.
If you’re a football fan as well as a stock investor, Cramer says, you’re in luck.
The Mad Money host says it's time to think about putting money to work. “Let me give you the list I have been working off of,” Cramer said.
If you’re a bull Cramer’s got news. Profiting from this market could get a lot harder.
Looking to buy? Cramer doesn’t want you to make a move before asking yourself this.
Biotech stocks are some of the best-performing S&P stocks this month. Chris Raymond, senior biotech analyst at Robert W. Baird, shares his top picks.